Supportive Care in Cancer · 2022 · 10 citations · 17 references
MedicineNephrologyOncologyChemotherapyMedical OncologyPalliative OncologyCancer Survival AnalysisColorectal CancerMetastatic Cancer ManagementPalliative ChemotherapySupportive Care In CancerAcute Kidney Injury PharmacotherapyColorectal Cancer PrognosisGlomerular Filtration Rate MeasurementPalliative Chemotherapy AdministrationPrognostic Factors AnalysisRenal Function CovariatesRenal Function EvaluationResidual Renal Function
PURPOSE: First-line choice of therapy is critical as it affects treatment decisions in later lines in patients with metastatic colorectal cancer (mCRC). We assessed changes in renal function for 1 year among patients diagnosed with mCRC who received first-line chemotherapy. We aimed to analyze the prognostic factors and effect of each chemotherapy regimen on the renal function of the patients. METHODS: We retrospectively investigated patients with mCRC who were treated with a standard triplet regimen (FOLFOX/FOLFIRI with bevacizumab/cetuximab) in the first-line setting at Korea University Anam Hospital from 2015 to 2020. We checked renal function at 3-month intervals for 12 months. We calculated changes in eGFR (△eGFR, estimated glomerular filtration rate) and compared them with clinical factors such as age, sex, chronic disease, body mass index (BMI), disease status, baseline proteinuria, and first-line chemotherapy regimen. RESULTS: . The 1-year incidence rate of acute kidney injury (AKI) was 9.1%, with the lowest occurrence in patients receiving FOLFOX/cetuximab (2.1%) and the highest in those receiving FOLFIRI + bevacizumab (19.2%). Renal dysfunction was more frequent with FOLFIRI + bevacizumab as compared to the other regimens. Additionally, old age, low BMI, and proteinuria at baseline were also associated with a decreased eGFR. CONCLUSIONS: These findings can serve as important factors when selecting the first-line chemotherapy regimen for patients with mCRC.
17
Colorectal cancer statistics, 2020
Rebecca L. Siegel, Kimberly D. Miller, Ann Goding Sauer et al. · CA A Cancer Journal for Clinicians · 2020 · 5.1K citations · Full text
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre et al. · New England Journal of Medicine · 2009 · 3.9K citations · Full text
Medicine, Oncology, Pharmacology +17
Leonard B. Saltz, Stephen Clarke, Eduardo Díaz‐Rubio et al. · Journal of Clinical Oncology · 2008 · 3K citations · Full text
Medicine, Oncology, Pharmacology +12